[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500190":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":29,"responsibleParty":53,"collaborators":18,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":18,"enrollmentInfo":65,"targetDuration":18,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":18,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Biological biomarker assessment","FFPE tumor tissue will be processed with a number of molecular biology techniques",[12],"Diagnostic Test: Biological biomarker assessment",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DIAGNOSTIC_TEST","IHC, PCR, NGS, methylome",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Alessandro Olivi, MD","CONTACT","+39 06 3015 4120","alessandro.olivi@policlinicogemelli.it",{"name":26,"role":22,"phone":27,"phoneExt":18,"email":28},"Rina Di Bonaventura, MD","+39 06 3015 1","rina.dibonaventura@guest.policlinicogemelli.it",[30],{"facility":31,"status":32,"city":33,"state":18,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Fondazione Policlinico Universitario A. Gemelli IRCCS","RECRUITING","Rome","00168","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],12.51133,41.89193,{"lat":41,"lon":40},[44,45,49,51],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"name":46,"role":22,"phone":47,"phoneExt":18,"email":48},"Roberto Pallini, MD, PhD","+39 06 3015 5414","roberto.pallini@unicatt.it",{"name":26,"role":50,"phone":18,"phoneExt":18,"email":18},"SUB_INVESTIGATOR",{"name":52,"role":50,"phone":18,"phoneExt":18,"email":18},"Q. Giorgio D'Alessandris, MD",{"type":54,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100500190","predictive-factors-for-survival-in-aggressive-meningiomas-100500190",false,"NCT05793034","Predictive Factors for Survival in Aggressive Meningiomas","Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma","23Men","Inclusion Criteria:\n\n1. Patient operated for atypical (grade 2) meningioma; or\n2. Patient operated for anaplastic (grade 3) meningioma;\n3. Timeframe for surgery, 1999-2019\n\nExclusion criteria\n\n1\\) Patient lost at follow-up","ALL","18 Years",{"count":66,"type":67},250,"ESTIMATED","INTERVENTIONAL",[70],"NA","The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.",[73,74,75],"Meningioma","Meningioma Atypical","Anaplastic Meningioma","2025-03-11",{"date":78,"type":79},"2025-03-13","ACTUAL",{"date":81,"type":79},"2021-01-07",{"date":83,"type":67},"2027-01-07",{"name":5,"class":6},1]